The Confidential Disclosure Agreement (“CDA”) is widely used in the Life Sciences Sector, and provides protection for a key asset – a party’s confidential information and trade secrets. This post does not propose to go through the various possible provisions of a CDA or their negotiation, but instead sets out five practical considerations to take into … Continue Reading
Non-disclosure or confidential disclosure agreements (“NDAs”) play an important role in the life science sector and are frequently used to allow parties to disclose information to each other as a prelude to a larger corporate or commercial transaction. The English courts have recently given us a timely reminder of the care that needs to be … Continue Reading
Taking a licence from a university or other academic institution raises specific considerations in addition to those that would normally apply in a purely commercial setting. We set out below ten key considerations for any commercial entity taking a licence from a university in the EU. 1. Continuing academic research in the field and publication … Continue Reading
On 11 July 2013, the ABI published the findings of its extensive review of processes for initial public offerings (IPOs) and secondary capital raisings in the UK public market. The ABI Report follows a government-funded independent review by Professor Kay (released July 2012), which examined investment in UK equity market and its impact on the … Continue Reading
Overview A one-way jurisdiction clause (also known as “hybrid”, “asymmetrical” or “unilateral non-exclusive” jurisdiction clauses), requires that one of the parties to a contract must always submit a dispute arising from the contract to a particular country’s courts, whilst allowing the other party the flexibility to commence proceedings in the courts of any country it … Continue Reading
OBR is a dynamic and energetic organisation which was founded in 2011 in Oxford, UK and now has chapters across the UK and the US. OBR’s mission is to engage academic and industry communities on-campus to foster a conversation about the health care and life sciences industry. OBR seeks to create a global network of … Continue Reading
Article originally published in PLC Life Sciences Handbook 2012 M&A in the life sciences sector has remained robust, driven by factors such as: The need to replenish shrinking product pipelines. The need to maintain revenues as patents on top-selling products expire. The strategic diversification of business lines. Expansion into emerging markets. … Continue Reading
Article originally published in The Lawyer on October 14, 2010 Despite global economic conditions, deal-making by large pharmaceutical companies has remained relatively buoyant, say Daniel Pavin, Grant Castle and Alexandra Pygall. Acquisitions in the pharmaceuticals sector are being driven by factors such as the need to replenish shrinking product pipelines, the need to maintain revenues … Continue Reading
Article originally published in the Cross-border Life Sciences Handbook 2006/07 Pharmaceutical and biotech companies are turning with increasing frequency to in-licensing and collaboration agreements – pharmaceutical companies to put new products in their pipelines and biotech companies to access the resources needed for final-stage development, clinical trials, manufacturing, and distribution. One result of the increasing importance … Continue Reading
